Myofibroblastic tumours: Neoplasias with divergent behaviour. Ultrastructural and flow cytometric analysis

Roberto Biselli, Renata Boldrini, Cristiano Ferlini, Camillo Boglino, Alessandro Inserra, Cesare Bosman

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Myofibroblasts are spindle cells having ultrastructural features in common with smooth muscle cells and fibroblasts. In the last few years, tumours have been described in which myofibroblasts represent not only a reactive mechanism but also a true neoplastic component. They constitute new nosologic entities which might be termed 'myofibroblastic tumours'. Tumours with benign and, rarely, malignant behaviour are reported to belong to this group of lesions. Recently, a third tumour type with borderline biological course, named 'inflammatory myofibroblastic tumour' (IMT), has been identified, a condition that has been regarded as a benign and reactive disorder for a long time. Only in recent reports has been demonstrated that, in spite of an apparently benign morphological pattern, some cases of IMT have a malignant course. In this connection, DNA analysis by flow cytometry is a valuable diagnostic tool, because it allows identification of the ploidy status, a procedure that is often useful for predicting the nature and the biological behaviour of the lesion. In this study, 11 cases of myofibroblastic tumours were examined retrospectively by evaluating clinicopathological features and DNA ploidy status by flow cytometry. The diagnosis of myofibroblastic tumour was confirmed by performing histology, immunohistochemistry, and electron microscopy in all patients. In detail, these 11 cases were composed of 1 benign myofibroblastoma, 1 myofibrosarcoma and 9 IMTs. Among these myofibroblastic tumours, all those with local recurrence or distant metastases (one myofibrosarcoma and three IMT) showed an aneuploid cell population demonstrable by flow cytometric analysis, whereas the other cases with benign course (one benign myofibroblastoma and six IMT) exhibited an euploid DNA content. These data suggest the following: a) Besides the rare myofibroblastomas and myofibrosarcomas, IMTs represent a larger group of lesions with potentially different biological and clinical course. b) DNA flow cytometric analysis is a reliable tool that supports histopathological examination in characterizing those cases of IMT that, though being malignant, mimic benign lesions. Consequently, it establishes the basis for a different therapeutic approach according to the euploid or aneuploid DNA content.

Original languageEnglish
Pages (from-to)619-632
Number of pages14
JournalPathology Research and Practice
Volume195
Issue number9
Publication statusPublished - 1999

Fingerprint

Neoplasms
Muscle Tissue Neoplasms
DNA
Myofibroblasts
Ploidies
Aneuploidy
Flow Cytometry
Adjustment Disorders
Smooth Muscle Myocytes
Histology
Electron Microscopy
Fibroblasts
Immunohistochemistry
Neoplasm Metastasis
Recurrence
Population
Therapeutics

Keywords

  • DNA content
  • Inflammatory myofibroblastic tumour
  • Inflammatory pseudotumour
  • Myofibroblastoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Myofibroblastic tumours : Neoplasias with divergent behaviour. Ultrastructural and flow cytometric analysis. / Biselli, Roberto; Boldrini, Renata; Ferlini, Cristiano; Boglino, Camillo; Inserra, Alessandro; Bosman, Cesare.

In: Pathology Research and Practice, Vol. 195, No. 9, 1999, p. 619-632.

Research output: Contribution to journalArticle

Biselli, Roberto ; Boldrini, Renata ; Ferlini, Cristiano ; Boglino, Camillo ; Inserra, Alessandro ; Bosman, Cesare. / Myofibroblastic tumours : Neoplasias with divergent behaviour. Ultrastructural and flow cytometric analysis. In: Pathology Research and Practice. 1999 ; Vol. 195, No. 9. pp. 619-632.
@article{521c62c7b7a843ddbc9b7a1ed3054557,
title = "Myofibroblastic tumours: Neoplasias with divergent behaviour. Ultrastructural and flow cytometric analysis",
abstract = "Myofibroblasts are spindle cells having ultrastructural features in common with smooth muscle cells and fibroblasts. In the last few years, tumours have been described in which myofibroblasts represent not only a reactive mechanism but also a true neoplastic component. They constitute new nosologic entities which might be termed 'myofibroblastic tumours'. Tumours with benign and, rarely, malignant behaviour are reported to belong to this group of lesions. Recently, a third tumour type with borderline biological course, named 'inflammatory myofibroblastic tumour' (IMT), has been identified, a condition that has been regarded as a benign and reactive disorder for a long time. Only in recent reports has been demonstrated that, in spite of an apparently benign morphological pattern, some cases of IMT have a malignant course. In this connection, DNA analysis by flow cytometry is a valuable diagnostic tool, because it allows identification of the ploidy status, a procedure that is often useful for predicting the nature and the biological behaviour of the lesion. In this study, 11 cases of myofibroblastic tumours were examined retrospectively by evaluating clinicopathological features and DNA ploidy status by flow cytometry. The diagnosis of myofibroblastic tumour was confirmed by performing histology, immunohistochemistry, and electron microscopy in all patients. In detail, these 11 cases were composed of 1 benign myofibroblastoma, 1 myofibrosarcoma and 9 IMTs. Among these myofibroblastic tumours, all those with local recurrence or distant metastases (one myofibrosarcoma and three IMT) showed an aneuploid cell population demonstrable by flow cytometric analysis, whereas the other cases with benign course (one benign myofibroblastoma and six IMT) exhibited an euploid DNA content. These data suggest the following: a) Besides the rare myofibroblastomas and myofibrosarcomas, IMTs represent a larger group of lesions with potentially different biological and clinical course. b) DNA flow cytometric analysis is a reliable tool that supports histopathological examination in characterizing those cases of IMT that, though being malignant, mimic benign lesions. Consequently, it establishes the basis for a different therapeutic approach according to the euploid or aneuploid DNA content.",
keywords = "DNA content, Inflammatory myofibroblastic tumour, Inflammatory pseudotumour, Myofibroblastoma",
author = "Roberto Biselli and Renata Boldrini and Cristiano Ferlini and Camillo Boglino and Alessandro Inserra and Cesare Bosman",
year = "1999",
language = "English",
volume = "195",
pages = "619--632",
journal = "Pathology Research and Practice",
issn = "0344-0338",
publisher = "Elsevier GmbH",
number = "9",

}

TY - JOUR

T1 - Myofibroblastic tumours

T2 - Neoplasias with divergent behaviour. Ultrastructural and flow cytometric analysis

AU - Biselli, Roberto

AU - Boldrini, Renata

AU - Ferlini, Cristiano

AU - Boglino, Camillo

AU - Inserra, Alessandro

AU - Bosman, Cesare

PY - 1999

Y1 - 1999

N2 - Myofibroblasts are spindle cells having ultrastructural features in common with smooth muscle cells and fibroblasts. In the last few years, tumours have been described in which myofibroblasts represent not only a reactive mechanism but also a true neoplastic component. They constitute new nosologic entities which might be termed 'myofibroblastic tumours'. Tumours with benign and, rarely, malignant behaviour are reported to belong to this group of lesions. Recently, a third tumour type with borderline biological course, named 'inflammatory myofibroblastic tumour' (IMT), has been identified, a condition that has been regarded as a benign and reactive disorder for a long time. Only in recent reports has been demonstrated that, in spite of an apparently benign morphological pattern, some cases of IMT have a malignant course. In this connection, DNA analysis by flow cytometry is a valuable diagnostic tool, because it allows identification of the ploidy status, a procedure that is often useful for predicting the nature and the biological behaviour of the lesion. In this study, 11 cases of myofibroblastic tumours were examined retrospectively by evaluating clinicopathological features and DNA ploidy status by flow cytometry. The diagnosis of myofibroblastic tumour was confirmed by performing histology, immunohistochemistry, and electron microscopy in all patients. In detail, these 11 cases were composed of 1 benign myofibroblastoma, 1 myofibrosarcoma and 9 IMTs. Among these myofibroblastic tumours, all those with local recurrence or distant metastases (one myofibrosarcoma and three IMT) showed an aneuploid cell population demonstrable by flow cytometric analysis, whereas the other cases with benign course (one benign myofibroblastoma and six IMT) exhibited an euploid DNA content. These data suggest the following: a) Besides the rare myofibroblastomas and myofibrosarcomas, IMTs represent a larger group of lesions with potentially different biological and clinical course. b) DNA flow cytometric analysis is a reliable tool that supports histopathological examination in characterizing those cases of IMT that, though being malignant, mimic benign lesions. Consequently, it establishes the basis for a different therapeutic approach according to the euploid or aneuploid DNA content.

AB - Myofibroblasts are spindle cells having ultrastructural features in common with smooth muscle cells and fibroblasts. In the last few years, tumours have been described in which myofibroblasts represent not only a reactive mechanism but also a true neoplastic component. They constitute new nosologic entities which might be termed 'myofibroblastic tumours'. Tumours with benign and, rarely, malignant behaviour are reported to belong to this group of lesions. Recently, a third tumour type with borderline biological course, named 'inflammatory myofibroblastic tumour' (IMT), has been identified, a condition that has been regarded as a benign and reactive disorder for a long time. Only in recent reports has been demonstrated that, in spite of an apparently benign morphological pattern, some cases of IMT have a malignant course. In this connection, DNA analysis by flow cytometry is a valuable diagnostic tool, because it allows identification of the ploidy status, a procedure that is often useful for predicting the nature and the biological behaviour of the lesion. In this study, 11 cases of myofibroblastic tumours were examined retrospectively by evaluating clinicopathological features and DNA ploidy status by flow cytometry. The diagnosis of myofibroblastic tumour was confirmed by performing histology, immunohistochemistry, and electron microscopy in all patients. In detail, these 11 cases were composed of 1 benign myofibroblastoma, 1 myofibrosarcoma and 9 IMTs. Among these myofibroblastic tumours, all those with local recurrence or distant metastases (one myofibrosarcoma and three IMT) showed an aneuploid cell population demonstrable by flow cytometric analysis, whereas the other cases with benign course (one benign myofibroblastoma and six IMT) exhibited an euploid DNA content. These data suggest the following: a) Besides the rare myofibroblastomas and myofibrosarcomas, IMTs represent a larger group of lesions with potentially different biological and clinical course. b) DNA flow cytometric analysis is a reliable tool that supports histopathological examination in characterizing those cases of IMT that, though being malignant, mimic benign lesions. Consequently, it establishes the basis for a different therapeutic approach according to the euploid or aneuploid DNA content.

KW - DNA content

KW - Inflammatory myofibroblastic tumour

KW - Inflammatory pseudotumour

KW - Myofibroblastoma

UR - http://www.scopus.com/inward/record.url?scp=0032873353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032873353&partnerID=8YFLogxK

M3 - Article

C2 - 10507082

AN - SCOPUS:0032873353

VL - 195

SP - 619

EP - 632

JO - Pathology Research and Practice

JF - Pathology Research and Practice

SN - 0344-0338

IS - 9

ER -